JY
NAMSW icon

Jeff Yass’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

Jeff Yass’s Portfolio NAMSW Stock Details NAMSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,319
Closed -$57.3K – 12928
2023
Q4 		$57.3K Buy
+18,319
New +$35.9K ﹤0.01% 11663

Other funds holding NAMSW

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $4.05B AUM 34.57% 1-Year Est. Return

Jeff Yass's NAMSW Position: Q1 2024 in Review

Jeff Yass sold out of NewAmsterdam Pharma Warrant (NAMSW) in Q1 2024, closing a stake of 18,319 shares — an estimated $57.3K sold.

Jeff Yass first reported a position in NAMSW in Q4 2023 and held it in 1 quarter. The position peaked at $57.3K in Q4 2023. 11 funds tracked by Wall St. Rank hold NAMSW as of Q1 2024.

  • Jeff Yass reported no remaining NewAmsterdam Pharma Warrant position as of Q1 2024 after selling out during the quarter.
  • Jeff Yass sold 18,319 NewAmsterdam Pharma Warrant shares in Q1 2024, an estimated $57.3K.
  • Jeff Yass first reported a position in NewAmsterdam Pharma Warrant in Q4 2023 and held it in 1 quarter.
  • Jeff Yass's NewAmsterdam Pharma Warrant position peaked at $57.3K in Q4 2023.
  • 11 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.